Use of antimicrobials in patients with COVID-19 without prior evaluation of an associated bacterial infection
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/20410 |
Resumo: | This paper aims to clarify and present discussions about the COVID-19 disease, its variants and prevention measures, as well as clarifying the excessive use of antimicrobials in the protocols of patients infected with it, as this practice can intensify an already existing public health problem, which is antimicrobial resistance. The methodology used in this research was a literature review on bacterial resistance due to the indiscriminate use of antimicrobials and the possible impacts caused in the COVID-19 pandemic, as well as the variants of worldwide concern, based on the Scientific Electronic Library Online databases - SCIELO, National Library of Medicine - PubMed, CAPES Journal Portal, Academic Google and National Health Surveillance Agency (ANVISA). Based on the literature presented here, it is concluded that COVID-19 is a disease caused by the acute respiratory syndrome (SARS-CoV-2) presenting a clinical spectrum ranging from asymptomatic infections to severe conditions. Several variants have emerged in several countries modifying the dynamics of transmissibility and potential immune flight from the disease, the Delta variant (B.1.617.2) being a greater threat to public health due to its high transmissibility. The misuse and excessive use of antimicrobials prescribed for the treatment of this disease can favor the emergence of superbugs and such resistance is a global problem. Therefore, the help of laboratory and clinical tests is essential to carry out a therapeutic intervention, observing the best options for each clinical case, since COVID-19 is a new disease and still under study. |
id |
UNIFEI_52ae9348e0b2e44e711103e62c573dfe |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/20410 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Use of antimicrobials in patients with COVID-19 without prior evaluation of an associated bacterial infectionUso de antimicrobianos en pacientes com COVID-19 sin evaluacíon previa de una infeccíon bacteriana asociadaUso de antimicrobianos em pacientes com COVID-19 sem avaliação prévia de uma infecção bacteriana associadaSARS-CoV-2 infectionAnti-infective agentsDrug resistance bacterial.Infeccíon por SARS-CoV-2Agente antimicrobianoFarmacorresistencia bacteriana.Infecção por SARS-CoV-2Agente antimicrobianoFarmacorresistência bacteriana.This paper aims to clarify and present discussions about the COVID-19 disease, its variants and prevention measures, as well as clarifying the excessive use of antimicrobials in the protocols of patients infected with it, as this practice can intensify an already existing public health problem, which is antimicrobial resistance. The methodology used in this research was a literature review on bacterial resistance due to the indiscriminate use of antimicrobials and the possible impacts caused in the COVID-19 pandemic, as well as the variants of worldwide concern, based on the Scientific Electronic Library Online databases - SCIELO, National Library of Medicine - PubMed, CAPES Journal Portal, Academic Google and National Health Surveillance Agency (ANVISA). Based on the literature presented here, it is concluded that COVID-19 is a disease caused by the acute respiratory syndrome (SARS-CoV-2) presenting a clinical spectrum ranging from asymptomatic infections to severe conditions. Several variants have emerged in several countries modifying the dynamics of transmissibility and potential immune flight from the disease, the Delta variant (B.1.617.2) being a greater threat to public health due to its high transmissibility. The misuse and excessive use of antimicrobials prescribed for the treatment of this disease can favor the emergence of superbugs and such resistance is a global problem. Therefore, the help of laboratory and clinical tests is essential to carry out a therapeutic intervention, observing the best options for each clinical case, since COVID-19 is a new disease and still under study.Este trabajo tiene como objetivo aclarar y presentar discusiones sobre la enfermedad COVID-19, sus variantes y medidas de prevención, así como aclarar el uso excesivo de antimicrobianos en los protocolos de los pacientes infectados por ella, ya que esta práctica puede intensificar un problema de salud pública ya existente, que es la resistencia a los antimicrobianos. La metodología utilizada en esta investigación fue una revisión de la literatura sobre la resistencia bacteriana por el uso indiscriminado de antimicrobianos y los posibles impactos causados en la pandemia de COVID-19, así como las variantes de preocupación mundial, a partir de las bases de datos Scientific Electronic Library Online - SCIELO, National Library of Medicine - PubMed, Portal de Periódicos CAPES, Google Acadêmico y Agencia Nacional de Vigilancia Sanitaria (ANVISA). Basándonos en la literatura presentada, concluimos que la COVID-19 es una enfermedad causada por el síndrome respiratorio agudo (SARS-CoV-2), con un espectro clínico que va desde las infecciones asintomáticas hasta los casos graves. Han surgido diversas variantes en varios países, cambiando la dinámica de la transmisibilidad y el potencial escape inmunológico de la enfermedad, siendo la variante Delta (B.1.617.2) una de las principales amenazas para la salud pública debido a su alta transmisibilidad. El uso inapropiado y excesivo de los antimicrobianos prescritos en el tratamiento de esta enfermedad puede favorecer la aparición de superbacterias y dicha resistencia es un problema mundial. Por lo tanto, la ayuda de los exámenes de laboratorio y clínicos es fundamental para realizar una intervención terapéutica observando las mejores opciones para cada caso clínico, ya que la COVID-19 es una nueva enfermedad aún en estudio.Este trabalho tem como objetivo esclarecer e apresentar discussões sobre a doença COVID-19, suas variantes e medidas de prevenção, bem como esclarecer quanto ao uso excessivo de antimicrobianos, nos protocolos de pacientes infectados pela mesma, uma vez que esta prática pode intensificar um problema de saúde pública, já existente, que é a resistência a antimicrobianos. A metodologia utilizada nesta pesquisa foi uma revisão de literatura sobre a resistência bacteriana pelo uso indiscriminado de antimicrobianos e os possíveis impactos causados na pandemia de COVID-19, bem como as variantes de preocupação mundial, baseou-se nos bancos de dados Scientific Electronic Library Online - SCIELO, National Library of Medicine - PubMed, Portal de Periódicos CAPES, Google Acadêmico e Agência Nacional de Vigilância Sanitária (ANVISA). Embasado na literatura aqui apresentada, conclui-se que A COVID-19 é uma doença causada pela síndrome respiratória aguda (SARS-CoV-2) apresentando um espectro clínico variando de infecções assintomáticas a quadro graves. Diversas variantes surgiram em vários países modificando a dinâmica de transmissibilidade e de potencial fuga imunitária da doença, sendo a variante Delta (B.1.617.2) uma ameaça maior à saúde pública devido sua alta transmissibilidade. O uso indevido e excessivo dos antimicrobianos prescritos no tratamento desta doença pode favorecer o surgimento de superbactérias e tal resistência é um problema global. Sendo assim, o auxílio de exames laboratoriais e clínicos é fundamental para fazer uma intervenção terapêutica observando as melhores opções para cada um dos casos clínicos, uma vez que a COVID-19 é uma doença nova e ainda em estudo.Research, Society and Development2021-09-19info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2041010.33448/rsd-v10i12.20410Research, Society and Development; Vol. 10 No. 12; e264101220410Research, Society and Development; Vol. 10 Núm. 12; e264101220410Research, Society and Development; v. 10 n. 12; e2641012204102525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/20410/18207Copyright (c) 2021 Déborah Demarque Martins da Silva; Jocelenne Cruz dos Santos; Lays Cordeiro de Jesus; Leandro da Conceição Luiz; Maria José Valenzuela Bell; Rafaela Tavares Batista; Virgílio de Carvalho dos Anjoshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSilva, Déborah Demarque Martins da Santos, Jocelenne Cruz dos Jesus, Lays Cordeiro de Luiz, Leandro da Conceição Bell, Maria José Valenzuela Batista, Rafaela Tavares Anjos, Virgílio de Carvalho dos 2021-11-14T20:26:51Zoai:ojs.pkp.sfu.ca:article/20410Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:40:04.052487Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Use of antimicrobials in patients with COVID-19 without prior evaluation of an associated bacterial infection Uso de antimicrobianos en pacientes com COVID-19 sin evaluacíon previa de una infeccíon bacteriana asociada Uso de antimicrobianos em pacientes com COVID-19 sem avaliação prévia de uma infecção bacteriana associada |
title |
Use of antimicrobials in patients with COVID-19 without prior evaluation of an associated bacterial infection |
spellingShingle |
Use of antimicrobials in patients with COVID-19 without prior evaluation of an associated bacterial infection Silva, Déborah Demarque Martins da SARS-CoV-2 infection Anti-infective agents Drug resistance bacterial. Infeccíon por SARS-CoV-2 Agente antimicrobiano Farmacorresistencia bacteriana. Infecção por SARS-CoV-2 Agente antimicrobiano Farmacorresistência bacteriana. |
title_short |
Use of antimicrobials in patients with COVID-19 without prior evaluation of an associated bacterial infection |
title_full |
Use of antimicrobials in patients with COVID-19 without prior evaluation of an associated bacterial infection |
title_fullStr |
Use of antimicrobials in patients with COVID-19 without prior evaluation of an associated bacterial infection |
title_full_unstemmed |
Use of antimicrobials in patients with COVID-19 without prior evaluation of an associated bacterial infection |
title_sort |
Use of antimicrobials in patients with COVID-19 without prior evaluation of an associated bacterial infection |
author |
Silva, Déborah Demarque Martins da |
author_facet |
Silva, Déborah Demarque Martins da Santos, Jocelenne Cruz dos Jesus, Lays Cordeiro de Luiz, Leandro da Conceição Bell, Maria José Valenzuela Batista, Rafaela Tavares Anjos, Virgílio de Carvalho dos |
author_role |
author |
author2 |
Santos, Jocelenne Cruz dos Jesus, Lays Cordeiro de Luiz, Leandro da Conceição Bell, Maria José Valenzuela Batista, Rafaela Tavares Anjos, Virgílio de Carvalho dos |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Silva, Déborah Demarque Martins da Santos, Jocelenne Cruz dos Jesus, Lays Cordeiro de Luiz, Leandro da Conceição Bell, Maria José Valenzuela Batista, Rafaela Tavares Anjos, Virgílio de Carvalho dos |
dc.subject.por.fl_str_mv |
SARS-CoV-2 infection Anti-infective agents Drug resistance bacterial. Infeccíon por SARS-CoV-2 Agente antimicrobiano Farmacorresistencia bacteriana. Infecção por SARS-CoV-2 Agente antimicrobiano Farmacorresistência bacteriana. |
topic |
SARS-CoV-2 infection Anti-infective agents Drug resistance bacterial. Infeccíon por SARS-CoV-2 Agente antimicrobiano Farmacorresistencia bacteriana. Infecção por SARS-CoV-2 Agente antimicrobiano Farmacorresistência bacteriana. |
description |
This paper aims to clarify and present discussions about the COVID-19 disease, its variants and prevention measures, as well as clarifying the excessive use of antimicrobials in the protocols of patients infected with it, as this practice can intensify an already existing public health problem, which is antimicrobial resistance. The methodology used in this research was a literature review on bacterial resistance due to the indiscriminate use of antimicrobials and the possible impacts caused in the COVID-19 pandemic, as well as the variants of worldwide concern, based on the Scientific Electronic Library Online databases - SCIELO, National Library of Medicine - PubMed, CAPES Journal Portal, Academic Google and National Health Surveillance Agency (ANVISA). Based on the literature presented here, it is concluded that COVID-19 is a disease caused by the acute respiratory syndrome (SARS-CoV-2) presenting a clinical spectrum ranging from asymptomatic infections to severe conditions. Several variants have emerged in several countries modifying the dynamics of transmissibility and potential immune flight from the disease, the Delta variant (B.1.617.2) being a greater threat to public health due to its high transmissibility. The misuse and excessive use of antimicrobials prescribed for the treatment of this disease can favor the emergence of superbugs and such resistance is a global problem. Therefore, the help of laboratory and clinical tests is essential to carry out a therapeutic intervention, observing the best options for each clinical case, since COVID-19 is a new disease and still under study. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-09-19 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/20410 10.33448/rsd-v10i12.20410 |
url |
https://rsdjournal.org/index.php/rsd/article/view/20410 |
identifier_str_mv |
10.33448/rsd-v10i12.20410 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/20410/18207 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 10 No. 12; e264101220410 Research, Society and Development; Vol. 10 Núm. 12; e264101220410 Research, Society and Development; v. 10 n. 12; e264101220410 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052690010734592 |